Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials

BACKGROUND: Although the addition of bevacizumab to 1(st )line chemotherapy provides a significant survival benefit for advanced colorectal cancer, the magnitudes of both advantages and toxicities have not been extensively investigated. METHODS: A literature-based meta-analysis was conducted; Hazard...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Loupakis, Fotios, Bria, Emilio, Vaccaro, Vanja, Cuppone, Federica, Milella, Michele, Carlini, Paolo, Cremolini, Chiara, Salvatore, Lisa, Falcone, Alfredo, Muti, Paola, Sperduti, Isabella, Giannarelli, Diana, Cognetti, Francesco
פורמט: Artigo
שפה:Inglês
יצא לאור: BioMed Central 2010
נושאים:
Research
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2890550/
https://ncbi.nlm.nih.gov/pubmed/20504361
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-9966-29-58
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים